• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Avelox (moxifloxacin) IV and tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – November 2009


Summary View



Postmarketing Adverse Event Reports
  • include the possibility of the exacerbation of the symptoms of myasthenia gravis associated with the use of moxifloxacin.